$1.7 Million Settlement – Medical Malpractice

Seeger Weiss Obtains $1.7 Million Recovery for Physician’s Failure to Diagnose Renal Disease in Timely Manner In a medical malpractice case pending in Supreme Court, Bronx County, Seeger Weiss came to a $1.7 million settlement agreement earlier this month on behalf of a client who has been diagnosed with end stage renal disease. The case, […]

August 9, 2010

Medical Malpractice

Seeger Weiss Obtains $1.7 Million Recovery for Physician’s Failure to Diagnose Renal Disease in Timely Manner

In a medical malpractice case pending in Supreme Court, Bronx County, Seeger Weiss came to a $1.7 million settlement agreement earlier this month on behalf of a client who has been diagnosed with end stage renal disease.

The case, brought against our client’s primary care physician, alleged that the physician’s failed to recognize signs and symptoms of kidney dysfunction over a period of nearly two years. In addition, this failure to diagnose and treat the client’s condition in its early stages was a significant factor in our client’s current diagnosis of advanced renal disease.

“This case underscores the importance of closely monitoring even routine blood test results,” said Seeger Weiss partner Marc S. Albert. “Simply put, this client’s kidney disease should have been diagnosed much earlier than it ultimately was. Unfortunately, blood tests over nearly a two year period, which showed elevated and continuously rising Creatinine and BUN levels—clear indications of renal disease—were not being carefully reviewed by his physician.”

During the course of the case, our client appeared on a CBS News special highlighting a problem that has become somewhat endemic in the medical field: physicians’ cavalier approach to reviewing patient’s test results. CBS, in a recent news story, reported on a number of patients—including our client—who had serious medical conditions slip through the cracks when test results were not carefully evaluated by their physician.

“We are extremely satisfied with what we feel is a just result for our client in this case,” said Mr. Albert.

Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA.

Related News

September 15, 2026
Lawdragon Names Seven Seeger Weiss Partners to 2027 500 Leading Litigators in America Guide

Lawdragon has recognized seven Seeger Weiss partners—Christopher Seeger, Stephen Weiss, Parvin Aminolroaya, Ben Barnett, David Buchanan, Shauna Itri, and Jennifer Scullion—in its 2027 Lawdragon 500 Leading Litigators in America guide. The guide highlights attorneys whose courtroom, investigative, and regulatory work has produced real impacts for the clients they represent, with many honorees credited with influencing entire […]

Read More
September 14, 2026
Seeger Weiss Recognized as a Finalist for Litigation Department of the Year, Products Liability/Mass Torts Category at the 2026 New Jersey Legal Awards

Seeger Weiss has been recognized as a finalist for Litigation Department of the Year, Products Liability/Mass Torts at the New Jersey Law Journal’s 2026 New Jersey Legal Awards. This recognition reflects a year of leadership appointments and firm growth across the department’s most significant matters. In March 2025, founding partner Christopher A. Seeger was appointed […]

Read More
September 2, 2026
Seeger Weiss Appointed as a Member of the Interim Plaintiffs’ Steering Committee in In re: Garden Grove Chemical Plant Evacuation Litigation

Seeger Weiss LLP has been appointed as a member of the Interim Plaintiffs’ Steering Committee in In re Garden Grove Chemical Plant Evacuation, a consolidated class action pending in the U.S. District Court for the Central District of California. Seeger Weiss founding partners Christopher A. Seeger and Stephen A. Weiss are leading the firm’s involvement […]

Read More